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Impact of screening and antiretroviral therapy
on anal cancer incidence in HIV-positive MSM
Nello Blasera,b,M, Barbara Bertischa,c,d,M, Roger D. Kouyose,
Alexandra Calmyf, Heiner C. Bucherg,h, Matthias Cavassinii,
Janne Estilla,d, Olivia Keisera,d,M, Matthias Eggera,j,M, for the
Swiss HIV Cohort Study
Background: The incidence of anal cancer is high in HIV-positive MSM. We modeled
the impact of screening strategies and combination antiretroviral therapy (cART)
coverage on anal cancer incidence in Switzerland.
Methods: Individual-based, dynamic simulation model parameterized with Swiss HIV
Cohort Study and literature data. We assumed all men to be human papillomavirus
infected. CD4þ cell count trajectories were the main predictors of anal cancer. From
2016 we modeled cART coverage either as below 100% (corresponding to 2010–2015)
or as 100%, and the following four screening strategies: no screening, yearly anal
cytology (Papanicolaou smears), yearly anoscopy and targeted anoscopy 5 years after
CD4þ count dropped below 200 cells/ml.
Results: Median nadir CD4þ cell count of 6411 MSM increased from 229 cells/ml
during 1980–1989 to 394 cells/ml during 2010–2015; cART coverage increased from 0
to 83.4%. Modeled anal cancer incidence peaked at 81.7/100 000 in 2009, plateaued
2010–2015 and will decrease to 58.7 by 2030 with stable cART coverage, and to 52.0
with 100% cART coverage. With yearly cytology, incidence declined to 38.2/100 000
by 2030, with yearly anoscopy to 32.8 and with CD4þ cell count guided anoscopy to
51.3. The numbers needed to screen over 15 years to prevent one anal cancer case were
384 for yearly cytology, 313 for yearly anoscopy and 242 for CD4þ cell count-
dependent screening.
Conclusion: Yearly screening of HIV-positive MSM may reduce anal cancer incidence
substantially, with a number needed to screen that is comparable with other screening
interventions to prevent cancer.
Copyright  2017 Wolters Kluwer Health, Inc. All rights reserved.
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Introduction
Anal cancer is caused by infection with high-risk types of
human papillomavirus (HPV) [1–3]. In HIV-negative
MSM, the incidence of anal cancer is around five per
100 000 person-years, which is about five times higher
than in the general population [1,2]. In HIV-positive
MSM, the incidence ranged between 78 and 168 per
100 000 person-years in studies from the era of
combination antiretroviral therapy (cART) [1,4–7].
The main risk factor for anal cancer is a history of
infection with high-risk types of HPV which is very
frequent in HIV-positive MSM [1–3,8]. Another
important risk factor is immunosuppression, character-
ized by low nadir CD4þ cell counts [4–6,9] or a long
duration of exposure to low CD4þ cell counts [10,11].
An analysis of the Swiss HIV Cohort Study (SHCS)
found that the strongest predictor was a low CD4þ cell
count 6–7 years before diagnosis [12]. Other potential
risk factors include smoking [2,12] and presence of
antibodies against high-risk HPV proteins [12].
Anal intraepithelial neoplasia (AIN) grades 2 or 3, the
precursors of anal cancer [2,3,13], are found in 24–50%
of HIV-positive MSM [1–3]. The progression from AIN
2/3 to anal cancer is estimated to range from 1.3 to 5.6%
over 5 years [1,3,13,14]. Screening for AIN 2/3 and
treatment of lesions can prevent progression to anal
cancer. Cytology based on Papanicolaou (Pap) smears of
the anal canal is inexpensive, but with 67–90% the
sensitivity is low in HIV-positive persons [15]. High-
resolution anoscopy and histology requires dedicated
equipment and training and is substantially more
expensive than cytology, but sensitivity is close to
100% [16]. Electrocautery and infrared (IR) coagulation
are the most effective treatments for intraanal AIN 2/3
[2]. Burgos et al. [17] found that 1 year after treatment
49% of patients were free of AIN 2/3; other studies
showed comparable or better results [18–20]. Although
only around half of men were free of AIN 2/3 after 1 year,
the treatment prevented progression to anal cancer in all
of them [18–20].
cART substantially decreases the risk of opportunistic
infections and cancers such as Kaposi sarcoma or non-
Hodgkin lymphoma [8,21], and similar decreases were
expected for anal cancer. However, studies suggest that
anal cancer incidence increased even after the widespread
introduction of cART [4,7–9]. For example, an analysis
of 13 cohorts from North America found that the
incidence of anal cancer continued to raise during the
early years of cART (1996–1999) and plateaued in the
2000s [7]. In the Netherlands, a slight decrease was
observed after 2006 [6].
The effectiveness of different screening strategies for anal
cancer is unclear and a matter of ongoing debate [1–3,7].
We developed a mathematical model and parameterized it
with data from the SHCS and the literature. We used the
model to study the impact of increasing the coverage of
cART, and of different screening strategies on the
incidence of anal cancer.
Methods
Structure of mathematical model
We developed an individual-based mathematical simu-
lation model to predict anal cancer incidence in HIV-
positive MSM in Switzerland, 1980–2030. We assumed
that all HIV-positive MSM were HPV-infected and
immunodeficiency (measured as trajectories of the CD4þ
positive lymphocyte cell count per ml) was the main risk
factor for anal cancer [12]. The model is a stochastic,
dynamic model and consists of a CD4þ cell count layer
and an anal cancer layer, which depends on the CD4þ cell
count layer (Fig. 1).
The CD4þ cell count layer of the model is a Markov
model, and the anal cancer part is a stochastic
compartmental model, where transition probabilities
are non-Markovian. In the CD4þ cell count layer, the
CD4þ trajectories of MSM are modeled across five CD4þ
cell count states (<100, 100–199, 200–349, 350–499
and 500 cells/ml). The anal cancer layer includes four
states of anal cancer progression (no precursor lesion,
AIN 1, AIN 2/3 and anal cancer). In the CD4þ cell count
layer, all transition times are piecewise exponentially
distributed. In the anal cancer layer, the rate of
progression from no lesion to AIN 1 is a function of
the CD4þ cell count f ðCD4þÞ ¼ b0  bCD4
þ=100
1
h i
.
The hazards of transitions from AIN 1 to AIN 2/3 and
from AIN 2/3 to anal cancer are Weibull distributed. The
hazard functions are, thus, of the form (k/l)(t/l)k1, in
which k is the shape parameter and l the scale parameter.
For the MSM who regressed from AIN 2/3 to AIN 1, the
time to regression was assumed to be 1 year after detection
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Fig. 1. Model structure with CD4R cell count and anal
cancer layers. The model is a stochastic, dynamic model.
The CD4þ cell count layer of the model is a Markov model
and the anal cancer layer a stochastic compartmental model,
where transition probabilities are non-Markov. AIN, anal
intraepithelial neoplasia.
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of AIN 2/3 and successful treatment. We compared
the predicted anal cancer incidence with the incidence
observed in MSM in the SHCS. For each of the
interventions described below, we simulated 10 000 000
HIV-positive MSM who were followed from 1980
to 2030.
We analyzed the SHCS to determine the parameters for the
CD4þ cell count layer, including probabilities of transition
between CD4þ cell count states and mortality. From 2016
onward, we used the parameters of 2010–2015. We used
published estimates for the anal cancer layer.
Analyses of Swiss HIV Cohort Study data
The SHCS is a prospective longitudinal study that
includes about 45% of all HIV-positive adults living in
Switzerland, and about 70% of all patients living with
AIDS [22]. Socio-demographic, behavioral, clinical,
laboratory data and use of cART regimens are recorded
at study entry and semiannual follow-up visits. We
included all MSM who had at least three CD4þ cell
counts. Follow-up started at estimated HIV infection date
[23]. We split follow-up into periods before cART
initiation and on cART. cARTwas defined as at least three
antiretroviral drugs from at least two drug classes. We
further split follow-up on cART into periods of successful
cART (viral load <1000 copies/ml) and failing cART
(viral load 1000 copies/ml). Within each calendar
period, we monotonically smoothed CD4þ trajectories
using a general additive model and predicted CD4þ cell
counts eight times a year. We fit a multistate model with
states determined by CD4þ cell counts (<100, 100–199,
200–349, 350–499 and500/ml) to six calendar periods
(1980–1989, 1990–1994, 1995–1999, 2000–2004,
2005–2009 and 2010–2015). We used the same calendar
periods and CD4þ cell count states to parameterize the
mortality rates of the MSM in our model.
Parameter estimates from literature
We chose the transition rate from no precursors of anal
cancer to AIN 1 in the baseline CD4þ category of 100–
199 cells/ml so that model simulations corresponded to
the anal cancer incidence of 78 per 100 000 person-years
reported by Machalek et al. [1]. We simulated the model
1000 times with 10 000 HIV-positive MSM and used
linear regression to identify the rate that matched this
incidence best. This rate was 0.15 per person-year
(b0¼ 0.15 in the equation for the hazard function f
above). We assumed that the rate of transition from no
lesion to AIN 1 increased by 2.04 per 100 000 for every
100/ml decrease in CD4þ cell count (b1¼ 2.04), based
on estimates from the SHCS [12]. We fit a Weibull
distribution to the cumulative incidence observed by
Mathews et al. [14]. In their study progression from AIN
2/3 to anal cancer was 2.1% [95% confidence interval
(CI) 1.3–2.8] after 2 years, and 3.9% (95% CI 2.1–5.6)
after 5 years. We found no published estimates for the
progression from AIN 1 to AIN 2/3. We, therefore, fit a
Weibull distribution to the progression from AIN 1 to
AIN 2/3, so that the progression from AIN 1 to anal
cancer lasted approximately 6–7 years, in line with
observations from the SHCS [12]. The shape parameters
(k) and scale parameters (l) of these distributions and all
other literature-derived parameters are shown in Table 1.
Interventions
We examined the effect of 100% cART coverage and
screening for AIN 2/3 and treatment on anal cancer
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Table 1. Parameter values progression and regression between precursor states and anal cancer.
Progression/regression
From To Parameter Value Source Reference
AIN 0 AIN 1 Rate per person-year with 100–199
CD4þ cells/ml
0.15a,b (0.1–0.2) Systematic review and meta-
analysis of longitudinal
studies in MSM
[1]
AIN 0 AIN 1 Increase in rate per person-year per
100 cells/ml CD4þ cell count decrease
2.04 (1.44–2.88) Case-control study nested
within Swiss HIV Cohort
Study, data from MSM
[12]
AIN 1 AIN 2/3 Weibull shape 2b (1–4) Idem [12]
AIN 1 AIN 2/3 Weibull scale 7b (5–10) Idem [12]
AIN 2/3 Anal cancer Weibull shape 0.69b (0.53–0.77) Cytology-based screening
cohort, overall data
(78% MSM)
[14]
AIN 2/3 Anal cancer Weibull scale 551.13b (201.2–7395.9) Idem [14]
AIN 2/3 AIN 1 Sensitivity of anal cytology (Pap
smears) %)
81 (69–93) Systematic review of test
accuracy studies in MSM and
other populations
[24]
AIN 2/3 AIN 1 Treatment efficacy 1 year after
treatment (in %)
48.1b (39.7–57.8) Retrospective cohort study of
MSM treated in surgical practice
[17]
AIN, anal intraepithelial neoplasia; Pap, Papanicolaou.
aIdentified through model simulations (see text).
bCalculated from data presented in cited publication.
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incidence in MSM. In the base scenario with cART
coverage below 100% and no screening, we assumed that
the cART coverage achieved in 2010–2015 continued
2016–2030. We implemented the 100% cART coverage
scenario by parameterizing the model with the estimates
from patients on cART. We considered four different
screening strategies, combined with cART below 100%:
no screening, yearly cytology screening, yearly anoscopy
screening and a CD4þ cell count-dependent strategy. In
the CD4þ cell count-dependent strategy, we assumed that
only those MSM were screened who had had a CD4þ
nadir below 200 cells/ml; they underwent anoscopy 5
years after their CD4þ cell count had dropped below 200
cells/ml. We assumed that cytology had a sensitivity of
81% (95% CI: 69–93%) based on the study by Chiao et al.
[24], and that anoscopy, including the histological
examination of suspicious lesions, was 100% sensitive.
We assumed a response rate of 49% 1 year after treatment
initiation for electrocautery or IR coagulation [17–19,
25]. We assumed that treated patients who reverted back
to AIN 1 subsequently had the same probability of
developing AIN 2/3 as untreated men with AIN 1. For
each strategy, we recorded the number of anal cancer
diagnoses and the number of screening tests. We then
calculated the number of anal cancers prevented
compared with the no screening strategy and the number
of people who needed to be screened (NNS) to prevent
one anal cancer [26]. In all simulations, we introduced the
screening intervention in 2016.
Sensitivity analyses
We performed a multivariate probabilistic sensitivity
analysis. We sampled all model parameters 10 000 times
from a log-normal distribution and simulated a popu-
lation of 10 000 HIV-positive MSM for each sampled
parameter set. We used the percentage of anal cancers
prevented in each screening scenario as the main outcome
variable and calculated Pearson correlation coefficients
between all parameter values and outcomes to identify the
parameters to which the model was most sensitive.
Results are presented as incidence rates per 100 000
person-years, with 95% CI. In an additional sensitivity
analysis, we tested the assumption of stationary CD4þ
trajectories. We simulated anal cancer incidence between
1980 and 2015 based on the observed CD4þ trajectories
in the SHCS.
Results
We analyzed 6411 MSM with at least three CD4þ cell
counts whowere followed in the SHCS between February
1983 and August 2015. Men had between three and 170
CD4þ cell counts, totaling 175 827 measurements. Table 2
shows the characteristics of the cohorts of MSM followed
in the different calendar periods. Coverage with cART
increased from 0% in 1980–1989 to 83.4% in 2010–2015.
There were marked increases over time in rates of transition
from low to higher CD4þ cell count states (Supplemental
Digital Content Table S1, http://links.lww.com/QAD/
B109). For example, the rate of transition from CD4þ cell
count less than 100 cells/ml to at least 100 cells/ml increased
from 5.3 (95% CI 4.3–6.4) per 100 person-years in 1980–
1989 to 122.9 (95% CI 120.8–124.9) per 100 person-years
in 2010–2015. As expected, mortality rates increased with
decreasing CD4þ cell counts and were higher in earlier
calendar years than in later years (Supplemental Digital
Content Table S2, http://links.lww.com/QAD/B109).
Anal cancer incidence
Under the base scenario of cART coverage remaining at
the level reached in the period 2010–2015 (Table 2) and
with no screening, the simulated anal cancer incidence
rates increased until 2009, plateaued between 2010 and
2015 and decreased from 2015 onward. The highest rate
was simulated for 2009, at 81.7 new cases per 100 000
person-years. The rate declined by 28.2% to 58.7 per
100 000 person-years in 2030 (Fig. 2 and, for a version
with 95% CIs, Supplemental Digital Content Fig. S1,
http://links.lww.com/QAD/B109).
The simulated anal cancer rate was broadly consistent
with the incidence rate observed in the SHCS. Between
1997 and 2003, the observed incidence in the SHCS was
higher than the simulated rates, but estimates were based
on small numbers of cases and CIs were wide. The
simulated rates matched the observed rates closely from
2003 onward (Supplemental Digital Content Fig. S2,
http://links.lww.com/QAD/B109).
Impact of combination antiretroviral therapy
coverage and screening
When modeling anal cancer incidence under the
assumption of 100% cART coverage from 2016 onward,
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Table 2. Characteristics of cohorts of MSM enrolled in the Swiss HIV Cohort Study, by follow-up period.
Follow-up
period
No. of
men
CD4þ cells/ml
(median, IQR)
Nadir CD4þ cells/ml
(median, IQR)
Age (median,
IQR)
Current smoking
(%)
cART
coverage (%)
1980–1989 762 340 (140–545) 228.5 (60.0–440.0) 36.2 (29.9–43.5) n.a. 0
1990–1999 3018 283 (126–469) 120.0 (20.0–288.8) 38.5 (32.7–46.4) n.a. 45.5
2000–2009 4087 467 (351–613) 257.0 (165.0–373.5) 41.7 (36.1–48.4) 50.4 78.2
2010–2015 4538 576 (451–727) 394.0 (283.0–524.8) 46.4 (38.9–53.0) 44.3 83.4
cART, combination antiretroviral therapy; IQR, interquartile range; n.a., not assessed.
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the incidence decreased to 52.0 per 100 000 person-years
by 2030, rather than to 58.7 per 100 000 person-years
with the base scenario (Fig. 2), corresponding to a relative
reduction of 11.4% compared with the base scenario.
Yearly anoscopy and subsequent treatment decreased anal
cancer incidence to 32.8 per 100 000 person-years in
2030, for a reduction of 44.1% compared with the base
scenario. Yearly cytology decreased anal cancer incidence
to 38.2 per 100 000 person-years in 2030, for a reduction
of 34.9%. Finally, CD4þ cell count-dependent anoscopy
decreased anal cancer incidence to 51.3 per 100 000
person-years in 2030, for a reduction of 12.6%. The
decrease in anal cancer incidence was substantial in the
first year after introducing screening. Afterwards the slope
was similar to the one observed with the base scenario
(Fig. 2).
Table 3 shows the number of expected anal cancer cases,
the number of screening tests, the number of cancer cases
prevented and the NNS of MSM to prevent one cancer in
a hypothetical cohort of 10 000 MSM followed up 2016–
2030. With yearly Pap screening, 384 MSM would need
to be screened for 15 years to prevent one case. Similarly,
with the yearly anoscopy strategy, 313 MSM would need
to be screened for 15 years to prevent one new case of anal
cancer. With CD4þ cell count-dependent screening, 242
MSM would need to be screened once to prevent one
anal cancer, but the percentage of cases prevented would
be smaller than with the other strategies.
Sensitivity analyses
The results of the sensitivity analyses are shown in
Supplemental Digital Content Figs. S3 and S4, http://
links.lww.com/QAD/B109. All strategies were sensitive
to the efficacy of electrocautery or IR coagulation
treatment (Pearson correlation r¼ 0.46 for yearly
anoscopy, r¼ 0.38 for yearly cytology and r¼ 0.20 for
CD4þ-dependent anoscopy). The benefit of the CD4þ
cell count-dependent anoscopy screening strategy was
most sensitive to the relationship between the risk of
transition from AIN 0 to AIN 1 and the CD4þ cell count
(r¼ 0.55). The benefit of yearly cytology was also
dependent on the sensitivity of cytology screening
(r¼ 0.23). The shape parameter of the Weibull distri-
bution used in the transition from AIN 2/3 to anal cancer
correlated with the percentage of anal cancers prevented
in all three screening strategies (r¼ 0.13, 0.09, 0.09,
respectively). Other correlations, including all corre-
lations with transitions between CD4þ cell count states
(Supplemental Digital Content Fig. S4, http://
links.lww.com/QAD/B109) were weak, with correlation
coefficients below 0.1. In the sensitivity analysis using
observed CD4þ trajectories the same pattern was evident,
with simulated anal cancer incidence rates increasing until
2007 and then plateauing. However, the peak of the
incidence was somewhat higher than in the simulation
with stationary CD4þ trajectories (Supplemental Digital
Content Fig. S5, http://links.lww.com/QAD/B109).
Discussion
This modeling study based on data from the SHCS
predicted that anal cancer incidence in HIV-positive
MSM peaked in 2009 at around 80 new cases per 100 000,
plateaued in subsequent years and will decrease to about
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Table 3. Comparison of anal cancer screening strategies in a cohort of 10000 MSM, followed from 2016 to 2030.
Strategy
No. of expected
invasive
cancer cases
No. of
screening
tests
No. of
cancers
prevented
No. of men needed
to be screened to
prevent one cancer
Percentage of
cases prevented
No. of screening
tests to prevent
one cancer
No screening 81.7 (65–100) 0 0.0 NA 0% NA
Yearly cytology 56.5 (42–72) 118 150 25.2 (16–35) 384 (347–422) 30.9% (30.0–31.8%) 4684 (4586–4782)
Yearly anoscopy 50.8 (37–65) 118 066 30.9 (21–42) 313 (279–347) 37.9% (36.9–38.8%) 3817 (3722–3913)
CD4þ cell count-
dependent anoscopya
71.1 (55–88) 2562 10.6 (5–17) 242 (212–272) 13.0% (12.3–13.6%) 242 (212–272)
Results from mathematical modeling study over 15 years (2016–2030). Estimates with 95% confidence intervals are shown.
aMen are screened 5 years after their CD4þ cell count fell below 200 cells/ml; 25.6% of men were eligible for CD4þ cell count-dependent
screening.
Fig. 2. Simulated anal cancer incidence assuming different
intervention scenarios.
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60 per 100 000 by 2030 in the absence of screening.
Universal cART coverage from 2016 onward would
reduce incidence further, to around 50 per 100 000 by
2030. Annual screening with Pap smears or anoscopy
would reduce anal cancer incidence substantially, to
below 40 per 100 000, and targeted screening of MSM
based on the CD4þ cell count nadir to about 50 per
100 000. The NNS of MSM over 15 years to prevent one
case were 384 for yearly cytology, 313 for yearly anoscopy
and 242 for CD4þ cell count-dependent screening.
To our knowledge, this is the first study to predict the
incidence of anal cancer in HIV-positive MSM over many
years, taking into account cART coverage and individual
CD4þ cell count trajectories. We used a dynamic stochastic
simulation model to estimate anal cancer incidence, based
on changes in CD4þ trajectories following the introduc-
tion of cART and allowing for nonconstant rates in
progression to anal cancer. Previous studies of the effect of
screening for precancerous anal lesions and cancer did not
consider the time-dependent effect of CD4þ cell count on
the risk of anal cancer [27,28]. The CD4þ cell count layer
of the model was parameterized with data from the SHCS,
one of the longest-running HIV cohort studies worldwide
[22,29]. The anal cancer layer was parameterized with data
from the literature but reproduced the incidence observed
in the Swiss cohort.
Our findings are consistent with several earlier studies
from Europe and the United States which reported that
during the first 10 years of cART anal cancer incidence
continued to rise [4,5,9]. Our results are also in line with
an analysis of North American cohorts which found that
anal cancer incidence plateaued beyond 10 years of cART
[7] and with findings from a Dutch cohort that observed a
slight decrease after 2006 [6]. Of note, rates of anal cancer
were higher in the North American and Dutch cohorts
than in our study. In the sensitivity analysis using the
observed instead of simulated CD4þ trajectories, we also
noted higher anal cancer incidence rates, but the overall
pattern was similar. Our study offers a possible
explanation for these trends, namely that during the
early study period many HIV-positive MSM initiated
cART at very low CD4þ cell counts, had already
progressed to AIN 1, and then lived long enough to
develop anal cancer.
Our study has several limitations. Smoking status was not
consistently recorded in the SHCS before the year 2000
and could, therefore, not be included in the model.
Furthermore, although we simulated follow-up of
patients until death, we did not explicitly model the
effect of aging. The rate of anal cancer increases with age
[2,7,8], but the effect of older age may be less important in
HIV-positive MSM, in whom anal cancer is seen at
younger ages than in other populations [4,9]. Our model
did not take effects of screening and treatment on HPV
transmission into account. The applicability of our results
to other countries and settings is unclear. It would be of
great interest to reparameterize our model in the context
of a different cohort of MSM. The shape of the epidemic
curve of anal cancer in HIV-positive MSM will likely be
similar in other countries where cART was introduced
rapidly, but the peak incidence reached, and the year of
the peak might differ. We did not include HPV clearance
in the model. Most anal cancers in MSM are caused by
HPV type 16 [1] and clearance of HPV type 16 is reduced
in HIV-positive individuals [30,31]. Also, integration of
HPV into the host genome of squamous cells [32] may
happen before HPV clearance.
We did not formally model cost-effectiveness. Goldie
et al. used a state-transition model to estimate the cost-
effectiveness of anal Pap screening in HIV-positive MSM
in the United States. The authors concluded that with an
incremental cost-effectiveness ratio of $13 000 (1997 US
dollars, 2-yearly screening in early stage of HIV) per
quality-adjusted life year (QALY) gained, such screening
offered ‘quality-adjusted life expectancy benefits at a cost
comparable with other accepted clinical preventive
interventions’ [27]. Czoski-Murray et al. [33] developed
decision-analytical models to evaluate the cost-effective-
ness of anal Pap screening in HIV-positive and HIV-
negative MSM in the United Kingdom. The authors
found little evidence that screening ‘would generate
health improvements at a reasonable cost’. The incre-
mental cost-effectiveness ratio in MSM, regardless of HIV
status, was over £44 000 (2007 pounds sterling) per
QALY gained. These discrepant findings are probably due
to different assumptions regarding the rate of progression
from AIN 2/3 to invasive cancer: the British study [33]
assumed that the rate of progression was relatively low,
and identical in HIV-positive and HIV-negative persons.
Although we did not model this explicitly, it becomes
clear from our study that the benefit of a screening
program would be greatest now and decrease over time as
fewer MSM have low nadir CD4þ, and more MSM have
been vaccinated against HPV.
How does screening for anal cancer in HIV-positive
MSM compare with screening for cervical cancer, which
is recommended by The United States Preventive
Services Task Force [34] and public health agencies in
many other countries? There are no randomized
controlled trials of cervical screening in Western
countries, and comparisons between women participat-
ing and not participating in screening programs are prone
to bias [35]. Raffle et al. [36] analyzed cervical screening
in the west of England 1976–1996 and estimated rates of
invasive cancer in the absence of screening based on
historical data: about 1800 women were needed to be
screened every 5 years during this period to prevent one
case of invasive cancer. In rural India, a cluster
randomized trial compared the effectiveness of a single
round of screening: the number of women needed to be
screened to prevent one cancer (stage II or higher) was
1864 AIDS 2017, Vol 31 No 13
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1258 for cytology and 684 for HPV testing [37]. Little
data are available on the effectiveness of screening in HIV-
positive women. A cost-effectiveness analysis based on
simulated practice in the United States showed that
screening with annual Pap smears was cost-effective [38],
and a simulation study of a cohort of HIV-positive
women in Cameroon concluded that 262 women will
need to be screened at cART initiation to prevent one
cervical cancer death [39]. Screening for colorectal cancer
and breast cancer is also widely recommended. An
Independent UK Panel on Breast Cancer Screening
concluded that 180 women would need to be screened
every 5 years from age 55 years to age 79 years to prevent
one breast cancer death [40]. Finally, a systematic review
and meta-analysis concluded that 377–515 asymptomatic
adults will need to undergo guaiac fecal occult blood
testing annually or biannually over 18 years to prevent one
colorectal cancer death [41].
In conclusion, our modeling study predicts substantial
reductions in anal cancer incidence in MSM in the next
15 years, even in the absence of screening and without
further increases in cART coverage. The model also
predicts that the introduction of yearly anal Pap screening
or anoscopy screening, or CD4þ cell count guided
anoscopy screening would reduce anal cancer incidence
further. It is noteworthy that NNS to prevent one invasive
anal cancer in MSM appear to be lower than the NNS to
prevent one invasive cervical cancer in HIV-negative
women, in whom screening is well established [42], and
that it may be similar to the NNS in HIV-positive
women. Clearly, further research on the cost-effective-
ness and acceptability of different strategies for anal cancer
screening is warranted. In the meantime, increasing
cART coverage further, in MSM and the HIV-positive
population in general, remains an important priority in
Switzerland and globally.
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